MEDIBANK PRIVATE LIMITED (MPL)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

MPL - MEDIBANK PRIVATE LIMITED

FNArena Sector : Insurance
Year End: June
GICS Industry Group : Insurance
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

Medibank Private is the largest Australian private health insurance provider. Previously an Australian Government business enterprise, established by the Whitlam government in 1975, it was privatised in 2014.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$3.21

18 May
2022

-0.030

OPEN

$3.23

-0.93%

HIGH

$3.24

10,248,370

LOW

$3.19

TARGET
$3.436 7.0% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
AMP . IAG . ISU . NHF . QBE . SDF . SUN . TWR . CVW . GDG . PSI . FCL .
FNARENA'S MARKET CONSENSUS FORECASTS
MPL: 1
Title FY20
Actual
FY21
Actual
FY22
Forecast
FY23
Forecast
EPS (cps) xxx 16.0 15.5 xxx
DPS (cps) xxx 12.7 12.9 xxx
EPS Growth xxx 40.0% - 3.2% xxx
DPS Growth xxx 5.8% 1.8% xxx
PE Ratio xxx N/A 20.6 xxx
Dividend Yield xxx N/A 4.0% xxx
Div Pay Ratio(%) xxx 79.3% 83.4% xxx

Dividend yield today if purchased 3 years ago: 4.41%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

3.97

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 04/03 - ex-div 6.1c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2022 FactSet UK Limited. All rights reserved
Title 201620172018201920202021
EPS Basic xxxxxxxxxxxxxxx16.0
DPS All xxxxxxxxxxxxxxx12.7
Sales/Revenue xxxxxxxxxxxxxxx6,984.4 M
Book Value Per Share xxxxxxxxxxxxxxx69.2
Net Operating Cash Flow xxxxxxxxxxxxxxx498.2 M
Net Profit Margin xxxxxxxxxxxxxxx6.32 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201620172018201920202021
Return on Capital Employed xxxxxxxxxxxxxxx23.72 %
Return on Invested Capital xxxxxxxxxxxxxxx22.82 %
Return on Assets xxxxxxxxxxxxxxx11.48 %
Return on Equity xxxxxxxxxxxxxxx23.72 %
Return on Total Capital xxxxxxxxxxxxxxx32.71 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx154.1 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

This is work in progress. Bear with us. It'll be amazing.

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.6

No. Of Recommendations

7
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Macquarie

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Credit Suisse

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

2

xxxxxxx xx xxxxxxxxxx xxxx xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

01/03/2022

3

Neutral

$3.25

1.25%

Following interim results for Medibank Private, UBS notes private health insurance continues to see greater policyholder engagement and participation as a result of the pandemic. It's felt rate deferrals will further boost participation.

The broker considers 1H results were solid and exceeded peers on the metrics of both customer acquisition and profit margin. Meanwhile, guidance was lifted slightly for FY22 insurance volumes and margins.

The analyst estimates covid-related tailwinds to persist into the 2H though therafter expects a reversal. The target slips to $3.25 from $3.50 and the Neutral rating is unchanged.

FORECAST
UBS forecasts a full year FY22 EPS of 15.00 cents.
UBS forecasts a full year FY23 EPS of 15.00 cents.

Morgans

xx/xx/xxxx

1

xxxxxxx xx xxx xxxx xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

1

xxxxxxx xx xxx xxxx xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

MPL STOCK CHART